Novo Nordisk’s Wegovy Achieves Weight-Loss of 20.7% at Higher Dose, Study Says
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side-effects.
Large study of Novo, Lilly weight loss drugs shows decrease in risk of Alzheimer's
As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s tirzepati | An observational study from Washington University in St.
E-sellers of compounded weight-loss drugs fail to reveal risks, research shows
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do not inform patients of the risks associated with these medicines, according to a research letter published on Friday.
Novo, Lilly Weight-Loss Drugs Reduce Risk of Alzheimer’s, Study Shows. What It Means for the Stocks.
Weight-loss and diabetes drugs reduced the risk of developing Alzheimer’s, an independent study published Monday showed. Pharma giants Novo Nordisk and Eli Lilly look to be the main benefactors of GLP-1 medications turning into a “catch-all pill,
Massive study looks at benefits, risks of GLP-1 weight-loss drugs
As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival drug Zepbound,
Weight-loss drugs reduce risk of Alzheimer’s, large study shows
Analysis of drugs such as Ozempic finds a lower health risk for 42 conditions but a higher rate of disorders such as arthritis
New study on weight loss drugs
ABC News chief medical correspondent Dr. Tara Narula explains the findings of a new study on GLP-1 drugs commonly used for weight loss.
Study Shows Diabetes Drugs' Potential Beyond Weight Loss
A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing them as miracle drugs.
Researchers reveal benefits, risks linked to popular weight-loss drugs
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have rapidly emerged as game-changers in treating diabetes, heart disease, and obesity. Commonly marketed under brand names like Ozempic and Wegovy,
Weight loss drugs reduce risk for medical conditions and diseases, study shows
Researchers studied medical records of veterans who have diabetes. Prince Harry settles lawsuit with Murdoch papers after apology How To Invest In The S&P 500 (Step By Step) The Star Player Being Kept Out of Cooperstown by a Trash Can What the 14th Amendment says about birthright citizenship 10 Reliable Luxury Cars That Will Last You A Lifetime China's 'artificial sun' shatters nuclear fusion record by generating steady loop of plasma for 1,
Outsourcing-pharma1d
Novo Nordisk reports positive results for high-dose Wegovy formulation
Results from Novo Nordisk's STEP UP trial show that a high-dose formulation of Wegovy can significantly increase the weight ...
Novo Nordisk high dose weight loss data ‘a double edged sword,’ says BofA
After Novo Nordisk (NVO) reported results from its Phase 3b STEP UP trial, which showed that adults with obesity achieved a 20.7% weight loss ...
BioSpace5d
Novo Nordisk Links High-Dose Wegovy to Increased Weight Loss in Phase III Trial
Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
Is Novo Nordisk Stock a Buy?
Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...
Healio1d
STEP UP: High-dose semaglutide led to 21% weight loss for adults with obesity
Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.